Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber

Ken Ichiro Wakabayashi, Kazuhiro Hashiguchi, Sho Kanzaki, Masato Fujioka, Nobuaki Tanaka, Kayoko Kawashima, Kiyochika Suematsu, Hajime Yamamotoya, Manabu Iwasaki, Minoru Gotoh, Seiji Horibe, Kensei Naito, Kimihiro Okubo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pranlukast (PLK) is a leukotriene receptor antagonist (LTRA) that has been approved for treatment of asthma in patients of all ages and allergic rhinitis (AR) in adults but not for AR in children in Japan. This randomized, double-blind, placebo-controlled, crossover study used an artificial exposure chamber (OHIO Chamber) to investigate the efficacy and safety of PLK in children from 10 to 15 years old with seasonal AR (SAR) due to Japanese cedar (JC) pollen. Eighty-four subjects were enrolled and randomized to the treatment arm and 74 were included in the per protocol set. Subjects received either PLK dry syrup (DS) or placebo for 1 week. They were challenged with JC pollen in the OHIO Chamber for 3 hours. Total nasal symptom scores (TNSSs) were recorded every 30 minutes during the exposure. PLK DS treatment suppressed the TNSS changes from baseline significantly when compared with placebo. The difference in the least square means in TNSS between the PLK DS-treated group and placebo group was -0.37 (95% CI, -0.54, -0.20) with a value of p < 0.0001, showing that PLK DS significantly suppressed the nasal symptoms. Regarding specific nasal symptoms, PLK DS significantly suppressed sneezing, nasal discharge, and nasal obstruction. The effect of PLK DS on nasal obstruction was most prominent, with significant improvement relative to placebo beginning 60 minutes after the start of exposure. No serious adverse events were reported during the study. In this study, PLK DS is effective and safe for treatment in children with SAR.

Original languageEnglish
Pages (from-to)102-109
Number of pages8
JournalAllergy and Asthma Proceedings
Volume33
Issue number1
DOIs
Publication statusPublished - 2012 Jan

Fingerprint

Cryptomeria
Seasonal Allergic Rhinitis
Nose
Placebos
Nasal Obstruction
Pollen
Sneezing
Leukotriene Antagonists
pranlukast
Therapeutics
Least-Squares Analysis
Cross-Over Studies
Japan
Asthma
Safety

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber. / Wakabayashi, Ken Ichiro; Hashiguchi, Kazuhiro; Kanzaki, Sho; Fujioka, Masato; Tanaka, Nobuaki; Kawashima, Kayoko; Suematsu, Kiyochika; Yamamotoya, Hajime; Iwasaki, Manabu; Gotoh, Minoru; Horibe, Seiji; Naito, Kensei; Okubo, Kimihiro.

In: Allergy and Asthma Proceedings, Vol. 33, No. 1, 01.2012, p. 102-109.

Research output: Contribution to journalArticle

Wakabayashi, KI, Hashiguchi, K, Kanzaki, S, Fujioka, M, Tanaka, N, Kawashima, K, Suematsu, K, Yamamotoya, H, Iwasaki, M, Gotoh, M, Horibe, S, Naito, K & Okubo, K 2012, 'Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber', Allergy and Asthma Proceedings, vol. 33, no. 1, pp. 102-109. https://doi.org/10.2500/aap.2012.33.3517
Wakabayashi, Ken Ichiro ; Hashiguchi, Kazuhiro ; Kanzaki, Sho ; Fujioka, Masato ; Tanaka, Nobuaki ; Kawashima, Kayoko ; Suematsu, Kiyochika ; Yamamotoya, Hajime ; Iwasaki, Manabu ; Gotoh, Minoru ; Horibe, Seiji ; Naito, Kensei ; Okubo, Kimihiro. / Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber. In: Allergy and Asthma Proceedings. 2012 ; Vol. 33, No. 1. pp. 102-109.
@article{e79f6ce5734a4495a78cf5e855dac138,
title = "Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber",
abstract = "Pranlukast (PLK) is a leukotriene receptor antagonist (LTRA) that has been approved for treatment of asthma in patients of all ages and allergic rhinitis (AR) in adults but not for AR in children in Japan. This randomized, double-blind, placebo-controlled, crossover study used an artificial exposure chamber (OHIO Chamber) to investigate the efficacy and safety of PLK in children from 10 to 15 years old with seasonal AR (SAR) due to Japanese cedar (JC) pollen. Eighty-four subjects were enrolled and randomized to the treatment arm and 74 were included in the per protocol set. Subjects received either PLK dry syrup (DS) or placebo for 1 week. They were challenged with JC pollen in the OHIO Chamber for 3 hours. Total nasal symptom scores (TNSSs) were recorded every 30 minutes during the exposure. PLK DS treatment suppressed the TNSS changes from baseline significantly when compared with placebo. The difference in the least square means in TNSS between the PLK DS-treated group and placebo group was -0.37 (95{\%} CI, -0.54, -0.20) with a value of p < 0.0001, showing that PLK DS significantly suppressed the nasal symptoms. Regarding specific nasal symptoms, PLK DS significantly suppressed sneezing, nasal discharge, and nasal obstruction. The effect of PLK DS on nasal obstruction was most prominent, with significant improvement relative to placebo beginning 60 minutes after the start of exposure. No serious adverse events were reported during the study. In this study, PLK DS is effective and safe for treatment in children with SAR.",
author = "Wakabayashi, {Ken Ichiro} and Kazuhiro Hashiguchi and Sho Kanzaki and Masato Fujioka and Nobuaki Tanaka and Kayoko Kawashima and Kiyochika Suematsu and Hajime Yamamotoya and Manabu Iwasaki and Minoru Gotoh and Seiji Horibe and Kensei Naito and Kimihiro Okubo",
year = "2012",
month = "1",
doi = "10.2500/aap.2012.33.3517",
language = "English",
volume = "33",
pages = "102--109",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Pranlukast dry syrup inhibits symptoms of Japanese cedar pollinosis in children using OHIO Chamber

AU - Wakabayashi, Ken Ichiro

AU - Hashiguchi, Kazuhiro

AU - Kanzaki, Sho

AU - Fujioka, Masato

AU - Tanaka, Nobuaki

AU - Kawashima, Kayoko

AU - Suematsu, Kiyochika

AU - Yamamotoya, Hajime

AU - Iwasaki, Manabu

AU - Gotoh, Minoru

AU - Horibe, Seiji

AU - Naito, Kensei

AU - Okubo, Kimihiro

PY - 2012/1

Y1 - 2012/1

N2 - Pranlukast (PLK) is a leukotriene receptor antagonist (LTRA) that has been approved for treatment of asthma in patients of all ages and allergic rhinitis (AR) in adults but not for AR in children in Japan. This randomized, double-blind, placebo-controlled, crossover study used an artificial exposure chamber (OHIO Chamber) to investigate the efficacy and safety of PLK in children from 10 to 15 years old with seasonal AR (SAR) due to Japanese cedar (JC) pollen. Eighty-four subjects were enrolled and randomized to the treatment arm and 74 were included in the per protocol set. Subjects received either PLK dry syrup (DS) or placebo for 1 week. They were challenged with JC pollen in the OHIO Chamber for 3 hours. Total nasal symptom scores (TNSSs) were recorded every 30 minutes during the exposure. PLK DS treatment suppressed the TNSS changes from baseline significantly when compared with placebo. The difference in the least square means in TNSS between the PLK DS-treated group and placebo group was -0.37 (95% CI, -0.54, -0.20) with a value of p < 0.0001, showing that PLK DS significantly suppressed the nasal symptoms. Regarding specific nasal symptoms, PLK DS significantly suppressed sneezing, nasal discharge, and nasal obstruction. The effect of PLK DS on nasal obstruction was most prominent, with significant improvement relative to placebo beginning 60 minutes after the start of exposure. No serious adverse events were reported during the study. In this study, PLK DS is effective and safe for treatment in children with SAR.

AB - Pranlukast (PLK) is a leukotriene receptor antagonist (LTRA) that has been approved for treatment of asthma in patients of all ages and allergic rhinitis (AR) in adults but not for AR in children in Japan. This randomized, double-blind, placebo-controlled, crossover study used an artificial exposure chamber (OHIO Chamber) to investigate the efficacy and safety of PLK in children from 10 to 15 years old with seasonal AR (SAR) due to Japanese cedar (JC) pollen. Eighty-four subjects were enrolled and randomized to the treatment arm and 74 were included in the per protocol set. Subjects received either PLK dry syrup (DS) or placebo for 1 week. They were challenged with JC pollen in the OHIO Chamber for 3 hours. Total nasal symptom scores (TNSSs) were recorded every 30 minutes during the exposure. PLK DS treatment suppressed the TNSS changes from baseline significantly when compared with placebo. The difference in the least square means in TNSS between the PLK DS-treated group and placebo group was -0.37 (95% CI, -0.54, -0.20) with a value of p < 0.0001, showing that PLK DS significantly suppressed the nasal symptoms. Regarding specific nasal symptoms, PLK DS significantly suppressed sneezing, nasal discharge, and nasal obstruction. The effect of PLK DS on nasal obstruction was most prominent, with significant improvement relative to placebo beginning 60 minutes after the start of exposure. No serious adverse events were reported during the study. In this study, PLK DS is effective and safe for treatment in children with SAR.

UR - http://www.scopus.com/inward/record.url?scp=84857490225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857490225&partnerID=8YFLogxK

U2 - 10.2500/aap.2012.33.3517

DO - 10.2500/aap.2012.33.3517

M3 - Article

C2 - 22370535

AN - SCOPUS:84857490225

VL - 33

SP - 102

EP - 109

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 1

ER -